^
    3ms
    GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=5, Active, not recruiting, Suzhou Kintor Pharmaceutical Inc, | Recruiting --> Active, not recruiting | N=105 --> 5 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2023 --> Apr 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Opdivo (nivolumab) • ascrinvacumab (GT90001)
    3ms
    A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Recruiting, Suzhou Kintor Pharmaceutical Inc, | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    erfonrilimab (KN046) • ascrinvacumab (GT90001)
    3ms
    Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) (clinicaltrials.gov)
    P1/2, N=20, Completed, Suzhou Kintor Pharmaceutical Inc, | Active, not recruiting --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • ascrinvacumab (GT90001)
    over2years
    A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Recruiting, Suzhou Kintor Pharmaceutical Inc, | Not yet recruiting --> Recruiting
    Clinical • Enrollment open • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    erfonrilimab (KN046) • ascrinvacumab (GT90001)
    almost3years
    A Phase Ib/II Study of GT90001 Combined With KN046 in Solid Tumors (clinicaltrials.gov)
    P1/2, N=216, Not yet recruiting, Suzhou Kintor Pharmaceutical Inc,
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    erfonrilimab (KN046) • ascrinvacumab (GT90001)
    almost3years
    Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) (clinicaltrials.gov)
    P1/2, N=20, Active, not recruiting, Suzhou Kintor Pharmaceutical Inc, | Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    TGFB1 (Transforming Growth Factor Beta 1)
    |
    Opdivo (nivolumab) • ascrinvacumab (GT90001)
    3years
    PF-03446962 in Relapsed or Refractory Urothelial Cancer (clinicaltrials.gov)
    P2, N=14, Completed, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | N=45 --> 14
    Clinical • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PTEN (Phosphatase and tensin homolog) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • IL6 (Interleukin 6) • FLT1 (Fms-related tyrosine kinase 1)
    |
    ascrinvacumab (GT90001)
    over3years
    [VIRTUAL] Safety and efficacy of combination of GT90001, an anti-activin receptor-like kinase-1 (ALK-1) antibody, and nivolumab in patients with metastatic hepatocellular carcinoma (HCC). (ASCO-GI 2021)
    This study aimed to assess the safety and efficacy of GT90001 in combination with nivolumab in patients with advanced HCC who had progressive disease after or were intolerant to first-line sorafenib or lenvatinib therapy (NCT03893695). The combination of GT90001 with nivolumab showed a manageable safety profile, and no new safety signals were identified. The promising preliminary antitumor activities show the potential of GT90001 combined with nivolumab as second-line treatment for advanced HCC.
    Clinical
    |
    ALK1 (Activin A Receptor Like Type 1)
    |
    Opdivo (nivolumab) • sorafenib • Lenvima (lenvatinib) • ascrinvacumab (GT90001)